NCT04278144: An ongoing trial by Bolt Biotherapeutics, Inc.
This trial is ongoing. It must report results 3 days, 20 hours from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04278144 |
|---|---|
| Title | Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 24, 2020 |
| Completion date | Dec. 10, 2024 |
| Required reporting date | Dec. 10, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |